Market Outlook

By 2035, the U.S. Elastomeric Infusion Pumps Market is expected to reach approximately USD 0.50 billion, expanding at a CAGR of 8.10% during the forecast period 2026–2035. The market is estimated at approximately USD 0.23 billion in 2025, following expansion from nearly USD 0.17 billion in 2021, USD 0.18 billion in 2022, USD 0.20 billion in 2023, and USD 0.21 billion in 2024. Values throughout this report are expressed in USD billions.

The U.S. elastomeric infusion pumps industry occupies a strategically important position within ambulatory drug delivery despite its comparatively modest revenue base. Elastomeric pumps are single-use, non-electronic infusion systems that use the elastic force of a reservoir to deliver medication at a predetermined or adjustable flow rate. Their economic importance is disproportionately large relative to device revenue because they can facilitate earlier discharge, outpatient treatment, home administration of intravenous therapies, continuous postoperative analgesia, ambulatory chemotherapy, and outpatient parenteral antimicrobial therapy.

Growth through 2035 will be supported by the convergence of four major forces: the continuing decentralization of infusion care, rising oncology treatment volumes, expansion of home and ambulatory antibiotic therapy, and pressure on hospitals to reduce avoidable bed days. Unlike electronic ambulatory pumps, elastomeric systems do not require batteries, programming interfaces, charging infrastructure, or extensive device retrieval and maintenance. This makes them attractive for defined-duration therapies where simplicity, portability, predictable administration, and reduced equipment management are prioritized.

The commercial opportunity is becoming more sophisticated, however. Buyers are increasingly evaluating pumps not simply as disposable devices but as components of complete infusion pathways involving pharmacy compounding, drug stability, catheter management, patient education, nursing support, flow-rate accuracy, leakage prevention, drug compatibility, reimbursement, and post-discharge follow-up. Manufacturers capable of supporting these workflow requirements are likely to secure stronger positions than suppliers competing primarily on unit price.

The forecast implies market expansion from approximately USD 0.25 billion in 2026 to USD 0.34 billion by 2030 and approximately USD 0.50 billion by 2035. The faster-growth portions of the market will include home infusion, outpatient antimicrobial therapy, oncology infusion, continuous peripheral nerve-block applications, variable-rate products, and higher-capacity reservoirs suited to multihour or multiday administration.

 

Introduction

According to the U.S. Elastomeric Infusion Pumps Market Report, the industry is being reshaped by the movement of clinically appropriate infusion episodes away from conventional inpatient settings. U.S. health systems increasingly face pressure to protect bed capacity, reduce length of stay, improve discharge throughput, control labor costs, and provide treatment in lower-cost sites. Elastomeric infusion pumps directly support this shift because they enable controlled medication administration without requiring a powered electronic pumping platform.

The technology is particularly relevant to antibiotics, fluorouracil-based chemotherapy, postoperative local anesthetic delivery, selected pain-management protocols, chelation therapy, and other continuous or prolonged infusions. In oncology, portable elastomeric systems can allow appropriate patients receiving multihour chemotherapy protocols to spend less time attached to stationary infusion equipment. In antimicrobial therapy, they can support treatment outside the hospital for patients who still require intravenous medication. In surgery, continuous peripheral nerve-block systems can contribute to multimodal strategies designed to reduce reliance on systemic opioids.

The market is also supported by the scale of the underlying U.S. healthcare system. The country has more than 6,000 hospitals, a rapidly expanding ambulatory surgery infrastructure, sophisticated specialty-pharmacy networks, home infusion companies, oncology clinics, integrated delivery systems, and hospital-at-home programs. More than 61 million Americans are already aged 65 or older, creating a growing population exposed to cancer, orthopedic surgery, serious infections, chronic illness, and complex medication requirements.

Cancer represents one of the most important clinical demand pools. The United States was expected to record more than 2 million new cancer diagnoses in 2025. A meaningful subset of systemic chemotherapy protocols require extended infusion, creating recurring consumption opportunities for disposable ambulatory delivery devices. Because elastomeric systems are consumed on a treatment-cycle basis rather than installed as long-lived capital equipment, revenue growth is closely linked to patient throughput and infusion episodes.

Market development is therefore less dependent on large hospital capital budgets than electronic pump markets. Procurement decisions instead sit at the intersection of pharmacy, oncology, anesthesia, infection management, nursing, materials management, value analysis, and discharge planning. This creates a fragmented but recurring revenue model in which clinical reliability and workflow fit are critical.

 

Key Market Drivers: What’s Fueling the U.S. Elastomeric Infusion Pumps Market Boom?

The first major growth driver is the expansion of home and ambulatory infusion care. U.S. health systems increasingly seek to move suitable treatment episodes to the home, physician office, infusion center, or other outpatient environment. Elastomeric pumps are particularly suited to this model because they are portable, lightweight, disposable, mechanically driven, and comparatively simple for patients and caregivers to use after appropriate training.

The economic logic is compelling. An inpatient hospital bed is a scarce and high-cost resource. When a clinically stable patient requires continued intravenous antimicrobial therapy but does not require acute hospital services, an ambulatory delivery pathway can preserve capacity for higher-acuity cases. This makes elastomeric pumps part of a broader hospital throughput strategy rather than merely an infusion consumable. Integrated delivery networks increasingly evaluate these devices against potential reductions in unnecessary inpatient days, nursing workload, equipment logistics, and return visits.

A second major driver is outpatient parenteral antimicrobial therapy. Serious bacterial infections, osteomyelitis, complicated skin infections, selected bloodstream infections, prosthetic-joint infections, and other conditions can require prolonged intravenous therapy. The United States also continues to face a substantial antimicrobial-resistance burden, increasing the clinical complexity of infection management. Elastomeric pumps can enable prolonged or continuous antibiotic infusion outside traditional hospital settings when drug stability, patient selection, vascular access, and monitoring requirements are appropriate.

A third driver is oncology. More than 2 million new U.S. cancer cases annually create a large clinical base for chemotherapy and supportive infusion. Fluorouracil-containing regimens used in gastrointestinal and other cancers are among the established applications for ambulatory infusion. The value proposition extends beyond convenience. Oncology centers can use portable infusion approaches to optimize chair capacity, reduce time spent in infusion suites, and manage increasing patient volumes without proportional expansion of physical infrastructure.

Postoperative pain management represents another strategically important demand area. U.S. hospitals and ASCs have increasingly adopted multimodal analgesia protocols intended to improve recovery while reducing unnecessary exposure to opioids. Continuous local anesthetic delivery through elastomeric systems can be incorporated into selected orthopedic, abdominal, thoracic, and other surgical pathways. The growth opportunity is particularly relevant to high-volume outpatient orthopedic procedures where the ability to provide extended analgesia after discharge may support patient satisfaction and recovery objectives.

Medicare policy has also improved the strategic visibility of non-opioid pain technologies. Qualifying elastomeric pain-pump systems can receive separate payment in applicable hospital outpatient and ASC circumstances during the temporary federal non-opioid payment period. Although reimbursement varies by product, indication, payer, and site of care, improved payment recognition reduces one historical procurement barrier for qualifying postoperative pain technologies.

The aging U.S. population creates an additional structural driver. Older adults represent approximately 18% of the U.S. population and are more likely than younger individuals to experience cancer, orthopedic surgery, infections requiring intravenous treatment, and complex chronic disease. The population aged 65 and older is therefore becoming an increasingly important demand pool for ambulatory infusion devices.

Hospital and ASC capacity expansion further supports the market. The U.S. has approximately 6,400 Medicare-participating ASCs, and the number of centers has continued to rise as procedures migrate outside hospital inpatient environments. As orthopedic and other surgery moves outpatient, the demand for discharge-compatible analgesia and simple medication-delivery technologies increases.

Finally, pharmacy economics influence adoption. Elastomeric systems must fit drug stability windows, compounding workflows, refrigeration requirements, labeling procedures, fill volumes, and transportation processes. Providers increasingly prefer suppliers with broad pump configurations that allow pharmacy teams to select reservoir size and flow rate around specific medications rather than redesign workflows around a limited product portfolio.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in elastomeric infusion pumps is less visible than innovation in software-driven electronic pumps, but it is no less important. Competitive differentiation increasingly revolves around flow consistency, elastomer performance, drug compatibility, reservoir design, fill accuracy, filter configuration, tubing architecture, connector security, patient visibility, and ease of handling.

Flow-rate accuracy is a central area of engineering focus because elastomeric devices are affected by physical variables including temperature, viscosity, fill volume, device position, back pressure, and reservoir characteristics. Manufacturers are therefore working to improve flow restrictor design and reservoir consistency while providing clearer operating ranges and clinical instructions. For purchasers, the commercial question is not whether a pump has a nominal flow rate but how reliably it performs across real-world home and ambulatory conditions.

Variable-rate and bolus-capable systems represent another important innovation pathway. Fixed-rate devices remain central to routine antimicrobial and chemotherapy administration, while adjustable systems can provide greater flexibility for selected postoperative pain protocols. The market opportunity is strongest where adjustability improves clinical utility without introducing the programming complexity associated with electronic pumps.

Drug compatibility and reservoir materials are also becoming more strategically important. U.S. specialty pharmacies need products that support commonly compounded antibiotics, chemotherapy agents, and local anesthetics while maintaining appropriate stability. Manufacturers able to generate robust compatibility data across multiple concentrations, diluents, reservoir sizes, and environmental conditions can reduce validation burden for pharmacy customers.

Connectivity remains an emerging rather than mature feature in elastomeric pumps. Purely mechanical devices are valued precisely because they avoid batteries and electronics. The likely evolution is therefore not to transform every disposable pump into a sophisticated electronic system, but to surround the device with digital workflow tools such as barcode verification, smartphone-supported patient instructions, remote symptom reporting, adherence tracking, digital discharge documentation, and pharmacy inventory analytics.

Sustainability will also become more important. Elastomeric pumps are single-use products containing polymers, tubing, connectors, and packaging. Health systems increasingly evaluate waste generated by disposable medical technologies. Suppliers that reduce material intensity, packaging volume, transportation requirements, or environmental footprint without compromising safety may gain procurement advantages over the next decade.

 

Segmentation Insights

The U.S. Elastomeric Infusion Pumps Market is segmented on the basis of product type, application, end user, reservoir capacity, and geography.

 

By Product Type

Continuous-Rate Elastomeric Infusion Pumps

Continuous-rate pumps represent the largest product segment and are estimated to generate roughly three-fifths of U.S. market revenue in 2025. Their strength reflects simplicity, familiarity, broad clinical applicability, and compatibility with protocols requiring a predetermined administration rate.

These systems are extensively used for antibiotics, chemotherapy, and selected postoperative analgesic infusions. Fixed-rate designs are particularly well aligned with home infusion because they minimize adjustment requirements and can reduce patient interaction with the device. They also fit pharmacy standardization strategies in which a limited number of validated flow-rate and reservoir combinations are matched to commonly compounded therapies.

Growth will remain durable through 2035 because continuous-rate devices benefit directly from OPAT expansion and oncology treatment volumes. Competitive differentiation will depend on consistency of emptying, flow accuracy, reliable connectors, availability across different fill volumes, drug stability documentation, and supply continuity.

Variable-Rate Elastomeric Infusion Pumps

Variable-rate elastomeric pumps represent a smaller but faster-growing product category. These products allow clinicians to select or adjust infusion rates and, in some configurations, enable patient-controlled bolus administration.

The strongest opportunity is in postoperative regional anesthesia and pain management, where clinicians may need greater control over infusion intensity according to procedure type and anticipated analgesic requirements. Variable-rate pumps can provide a middle ground between fixed-rate disposable devices and more expensive electronic ambulatory pumps.

Growth in this segment will be supported by expansion of outpatient orthopedic surgery, enhanced-recovery pathways, opioid-sparing protocols, and Medicare recognition of qualifying non-opioid technologies. However, adjustable designs require particularly clear labeling and patient education because inappropriate manipulation may create dosing risk.

 

By Application

Antibiotics and OPAT

Antibiotic administration represents one of the largest and most strategically attractive applications, accounting for an estimated one-third of U.S. elastomeric pump demand in 2025. Continuous or extended infusion approaches can be useful for selected antimicrobial agents where pharmacokinetic objectives, stability, and clinical circumstances support prolonged administration.

The commercial opportunity is strongly linked to hospital discharge programs and home infusion pharmacy infrastructure. Hospitals seeking to release stable patients earlier can partner with infusion pharmacies and nursing organizations to continue therapy outside the acute-care environment. This produces recurring demand for pumps, tubing, vascular-access supplies, pharmacy compounding, monitoring, and patient education.

The segment is expected to outperform the broader market because U.S. providers are increasingly focused on reducing inpatient days while maintaining treatment continuity.

Chemotherapy

Chemotherapy is a core recurring application for elastomeric infusion pumps. Portable devices are particularly relevant to regimens involving prolonged fluorouracil administration and other suitable protocols requiring continuous infusion after the patient leaves an oncology facility.

The U.S. oncology ecosystem is structurally supportive because annual cancer incidence exceeds 2 million new diagnoses and treatment is distributed across academic cancer centers, hospital outpatient departments, community oncology practices, and integrated cancer networks. For high-volume centers, portable pumps can help protect infusion-chair capacity and allow patients to complete appropriate portions of therapy away from the clinic.

This segment places unusually high importance on flow reliability and complete drug delivery. A pump that fails to empty appropriately can create treatment delays, patient inconvenience, unplanned clinic contact, and potential dosing concerns. Product reliability therefore carries substantial clinical and reputational value.

Pain Management and Postoperative Analgesia

Pain management represents a high-value growth segment centered on local anesthetic delivery and continuous peripheral nerve-block applications. The segment benefits from the national movement toward multimodal pain management and the reduction of unnecessary opioid exposure.

Orthopedic procedures are especially relevant because many shoulder, knee, foot, ankle, and other surgeries are increasingly performed in outpatient settings. Patients may leave the facility on the day of surgery while still requiring meaningful analgesia during the early recovery period. Elastomeric pumps provide an option for extending local anesthetic delivery beyond the facility.

Reimbursement developments for qualifying non-opioid devices improve the economic discussion for hospital outpatient departments and ASCs. Procurement committees will nevertheless continue to assess catheter-related complications, patient education burden, leakage, flow control, return procedures, and overall episode economics.

Chelation Therapy

Chelation therapy remains a smaller application but provides recurring niche demand. Patients requiring prolonged infusion of selected chelating agents may benefit from portable delivery systems that reduce time connected to stationary infusion equipment.

Revenue contribution is limited relative to antibiotics, oncology, and postoperative pain, but the segment can be commercially attractive for manufacturers with suitable reservoir configurations and drug-compatibility evidence. Adoption is concentrated in specialist settings rather than broadly distributed across hospitals.

Other Applications

Other applications include selected antiviral, hydration, supportive-care, palliative, and specialty medication protocols. These use cases represent a relatively small share of market value but broaden the addressable customer base for manufacturers offering extensive pump configurations.

 

By End User

Hospitals and Health Systems

Hospitals and health systems represent the largest purchasing group and account for an estimated 40% of market revenue in 2025 when hospital outpatient activity is included. Their importance extends beyond direct consumption because hospitals initiate many infusion pathways that later transition to home-based care.

Large integrated delivery networks increasingly standardize elastomeric products through value-analysis committees and enterprise sourcing agreements. Procurement decisions consider acquisition cost, flow performance, pharmacy compatibility, clinician familiarity, leakage or malfunction history, packaging, supply reliability, and the ability to support multiple service lines using common products.

With more than 6,000 hospitals operating nationally, the addressable provider base is extensive, but purchasing power is increasingly concentrated among large health systems and group purchasing organizations.

Home Infusion and Home Healthcare Providers

Home infusion represents the fastest-growing end-user category and could become one of the defining channels through 2035. These providers coordinate medication preparation, pump distribution, patient education, nursing support, catheter management, and retrieval or disposal requirements.

Elastomeric pumps are highly compatible with home infusion economics because they avoid the capital management associated with electronic pumps. There is no battery charging, software maintenance, or expensive device fleet to recover after each episode. For disposable-treatment pathways, these operational advantages can materially simplify logistics.

However, reimbursement is complex. Disposable elastomeric systems do not automatically qualify as durable medical equipment merely because they deliver infused medication. Commercial success therefore depends on understanding the reimbursement mechanism for the underlying therapy and site of service rather than assuming pump-specific DME payment.

Ambulatory Surgery Centers

ASCs represent a rapidly expanding opportunity, particularly for postoperative pain management. Approximately 6,400 ASCs treated Medicare fee-for-service beneficiaries in 2024, demonstrating the scale of the addressable outpatient surgical infrastructure.

Orthopedic, general surgical, and other procedures continue to shift toward ambulatory settings as techniques, anesthesia, patient selection, and postoperative management improve. Elastomeric pain pumps can fit this model by extending analgesia after same-day discharge while avoiding electronic equipment management.

ASC purchasing behavior differs from large-hospital procurement. Centers tend to prioritize predictable per-case cost, simplicity, minimal staff training, rapid turnover, reliable supply, and reimbursement clarity. Manufacturers that can demonstrate a clear procedure-level economic case are positioned favorably.

Oncology and Specialty Infusion Centers

Community oncology practices and specialty infusion centers are strategically important because they generate recurring treatment-cycle consumption. These facilities frequently operate under capacity pressure, making infusion-chair utilization and patient throughput meaningful economic variables.

Pump selection is closely linked to pharmacy operations and treatment protocol standardization. Products that simplify filling, labeling, priming, patient education, and disconnect workflows can achieve strong retention once incorporated into standardized chemotherapy pathways.

Skilled Nursing, Post-Acute, and Other Providers

Skilled nursing facilities, post-acute providers, physician practices, and specialty clinics account for a smaller share of market revenue. Their opportunity is concentrated in antimicrobial therapy and selected prolonged infusions for patients who do not require acute hospitalization but may not be suitable for independent home administration.

 

By Reservoir Capacity

Less Than 100 mL

Smaller-volume elastomeric pumps are primarily relevant to concentrated medication delivery, selected pain-management protocols, and therapies where prolonged administration can be achieved without large fluid volumes. Their compact size supports patient mobility and convenience.

This segment benefits from the outpatient surgery market because regional anesthesia protocols can require relatively small reservoirs compared with multiday antibiotic therapy. Device ergonomics, secure catheter connections, and portability strongly influence product choice.

100 mL to 250 mL

The 100 mL to 250 mL category represents the largest reservoir-capacity segment because it provides flexibility across antibiotics, chemotherapy, and other ambulatory infusions. These volumes allow pharmacy teams to accommodate a broad range of drug concentrations and administration durations while maintaining a manageable device footprint.

Manufacturers with multiple flow-rate combinations within this reservoir range are positioned well for enterprise contracts because health systems and infusion pharmacies can standardize several protocols around a common device family.

More Than 250 mL

Higher-capacity pumps are used where therapy duration or fluid requirements make larger reservoirs operationally advantageous. They are particularly relevant to continuous antimicrobial administration and selected postoperative pain applications.

The segment should expand as providers become more comfortable treating clinically stable patients outside acute-care environments for longer durations. The key product challenge is balancing capacity with portability because heavier filled reservoirs may reduce patient convenience.

 

Regional Insights: Where the Market is Growing Fastest

The U.S. Elastomeric Infusion Pumps Market is geographically segmented into the South, West, Northeast, and Midwest. Regional performance reflects population scale, cancer burden, surgery volumes, hospital and ASC density, home infusion infrastructure, specialty-pharmacy presence, payer mix, urbanization, age distribution, and the maturity of hospital-at-home and OPAT programs.

The South is estimated to represent approximately USD 0.083 billion in 2025, making it the largest regional market. The West accounts for approximately USD 0.058 billion, the Northeast approximately USD 0.052 billion, and the Midwest approximately USD 0.037 billion. The West is expected to post the fastest percentage growth through 2035, while the South should remain the largest market by absolute revenue.

South

The South is the largest U.S. regional opportunity because it combines rapid population growth, large metropolitan health systems, a significant older-adult population, substantial cancer and chronic-disease burden, expanding ASC infrastructure, and broad home-health demand. The region is modeled to increase from approximately USD 0.083 billion in 2025 to around USD 0.18 billion by 2035.

The region includes Texas, Florida, Georgia, North Carolina, South Carolina, Virginia, West Virginia, Maryland, Delaware, Tennessee, Kentucky, Alabama, Mississippi, Arkansas, Louisiana, Oklahoma, and the District of Columbia, depending on the regional classification used by individual buyers. Each state presents a different mix of oncology, infection-management, surgery, and home-infusion demand.

Texas represents one of the largest state opportunities nationally. Houston, Dallas-Fort Worth, Austin, and San Antonio support extensive hospital networks, cancer programs, orthopedic surgery, specialty pharmacy, and home infusion services. Texas also combines large urban tertiary-care centers with geographically dispersed communities, increasing the strategic value of therapies that can be administered away from central hospitals.

Florida is equally important because of its large and aging population. Demand is particularly strong for oncology, orthopedic surgery, postoperative pain management, and home infusion. The state’s extensive outpatient healthcare infrastructure and high Medicare exposure make reimbursement strategy especially important for pump manufacturers.

North Carolina, Georgia, Tennessee, and Virginia are strong growth states because of expanding metropolitan populations and sophisticated referral systems. Major health systems in Charlotte, Raleigh-Durham, Atlanta, Nashville, Richmond, and Northern Virginia provide substantial opportunities for enterprise infusion standardization.

Maryland and Delaware benefit from dense healthcare infrastructure and proximity to major Northeast medical markets. South Carolina continues to expand ambulatory and home-based services as its population grows.

Alabama, Mississippi, Louisiana, Arkansas, Kentucky, Oklahoma, and West Virginia represent smaller revenue pools but potentially important OPAT markets. Several of these states face high chronic-disease burdens and substantial rural populations. For manufacturers, the opportunity is less about premium device complexity and more about reliable products that allow treatment to continue when patients live significant distances from tertiary hospitals.

The South should remain the largest market throughout the forecast period because demographic growth and care decentralization reinforce each other. Manufacturers seeking scale should prioritize enterprise health-system contracting in Texas and Florida while developing strong distributor and home-infusion relationships across secondary Southern states.

West

The West represents approximately USD 0.058 billion in 2025 and is expected to be the fastest-growing regional market, reaching approximately USD 0.14 billion by 2035. Growth will be driven by outpatient care innovation, hospital-at-home experimentation, sophisticated integrated delivery networks, strong specialty-pharmacy penetration, expanding ambulatory surgery, and early adoption of workflow technologies.

The region includes California, Washington, Oregon, Arizona, Nevada, Colorado, Utah, New Mexico, Idaho, Montana, Wyoming, Alaska, and Hawaii.

California is the dominant state market. Its large population, major academic centers, extensive oncology infrastructure, integrated health systems, specialty pharmacies, and dense outpatient care ecosystem create demand across antibiotics, chemotherapy, postoperative analgesia, and home infusion. California buyers are also relatively sensitive to labor economics. Technologies that reduce nursing workload or eliminate electronic-pump fleet management can therefore have meaningful value.

Arizona and Nevada are high-growth markets because of population expansion and increasing retiree populations. Both states are seeing continued growth in orthopedic surgery, oncology services, and outpatient care, creating favorable demand for elastomeric devices.

Washington and Oregon are important because of their sophisticated health-system networks and comparatively mature use of coordinated outpatient care. These markets are well positioned for standardized OPAT programs in which pharmacy, infectious-disease specialists, nursing teams, and digital follow-up are integrated.

Colorado and Utah combine younger population growth with expanding tertiary and specialty-care infrastructure. Both are attractive for ambulatory surgery and health-system contracting. New Mexico, Idaho, Montana, Wyoming, Alaska, and Hawaii have smaller absolute device markets but offer distinctive opportunities for home infusion because travel distances can make repeated facility-based administration operationally difficult.

The West is likely to gain national market share through 2035 because the region is particularly receptive to decentralized care models. Manufacturers that pair reliable disposable pumps with digital patient instruction, pharmacy analytics, and outcome documentation may achieve disproportionate growth.

Northeast

The Northeast represents approximately USD 0.052 billion in 2025 and is expected to approach USD 0.11 billion by 2035. It remains one of the most clinically sophisticated markets for oncology, infectious disease, surgery, and specialty infusion.

The region includes New York, Pennsylvania, New Jersey, Massachusetts, Connecticut, Rhode Island, New Hampshire, Vermont, and Maine, with Delaware sometimes grouped with the South depending on the analytic framework.

New York is the largest state opportunity in the Northeast. The market benefits from extremely high healthcare density, major academic medical centers, large cancer programs, extensive outpatient networks, and a significant home-care industry. New York City creates enormous procedure and infusion volumes, while upstate markets present opportunities for ambulatory care that reduces travel to tertiary centers.

Pennsylvania has large healthcare systems in Philadelphia, Pittsburgh, and other metropolitan areas and represents a strong market for oncology, OPAT, and orthopedic surgery. New Jersey combines high population density with substantial pharmaceutical, specialty-pharmacy, and outpatient healthcare infrastructure.

Massachusetts is strategically influential beyond its absolute market size. Boston’s academic medical centers frequently shape clinical protocols, evidence development, pharmacy standards, and technology evaluation. Manufacturers that gain adoption within these institutions may benefit from broader reputational credibility.

Connecticut and Rhode Island offer dense provider networks and relatively convenient access to specialty services. Maine, Vermont, and New Hampshire are smaller markets but have meaningful rural populations and older demographic profiles, making home infusion particularly relevant where patients live far from tertiary centers.

Northeast procurement is often evidence-intensive. Buyers are likely to scrutinize flow-rate performance, medication stability, human factors, device complaints, infection-management protocols, and total episode economics. Price remains important, but reliability and clinical documentation can carry greater weight than in purely commodity-oriented procurement.

Midwest

The Midwest represents approximately USD 0.037 billion in 2025 and is projected to reach approximately USD 0.076 billion by 2035. Growth is expected to be steady rather than explosive, supported by mature hospital systems, regional oncology networks, major orthopedic programs, specialty pharmacies, and substantial chronic-disease demand.

The region includes Illinois, Ohio, Michigan, Indiana, Wisconsin, Minnesota, Missouri, Iowa, Kansas, Nebraska, North Dakota, and South Dakota.

Illinois is the largest regional opportunity, driven by Chicago’s extensive academic, community-hospital, oncology, and ambulatory-care infrastructure. Large integrated health systems provide opportunities for standardized pump contracts across multiple facilities.

Ohio is another major market, with strong hospital networks in Cleveland, Columbus, Cincinnati, and surrounding areas. Oncology and complex infection management generate recurring ambulatory infusion demand.

Michigan combines a large population with mature healthcare infrastructure and significant chronic-disease burden. Indiana and Wisconsin offer stable demand across surgery, oncology, and OPAT, while Missouri provides meaningful volume through St. Louis and Kansas City health systems.

Minnesota has particular strategic importance because of its established medical-device ecosystem and sophisticated provider institutions. Although the state is smaller than Illinois or Ohio, clinical evaluation and procurement practices can influence broader industry adoption.

Iowa, Kansas, Nebraska, North Dakota, and South Dakota have smaller population bases but represent attractive settings for home and ambulatory infusion because patients may travel long distances for specialty care. Elastomeric pumps can help reduce repeated facility visits when clinical circumstances permit treatment outside the hospital.

The Midwest is likely to remain a dependable market for manufacturers that compete effectively on supply reliability, pharmacy support, contracting flexibility, and standardized clinical education. Rural reach and distributor execution are especially important outside the largest metropolitan areas.

 

Key Market Players

The U.S. Elastomeric Infusion Pumps competitive landscape is moderately fragmented. Unlike electronic infusion-pump markets dominated by a small number of large platforms, elastomeric infusion includes multinational medtech manufacturers, specialist disposable-infusion companies, regional suppliers, and international manufacturers seeking U.S. clearance and distribution.

Among the most relevant companies participating directly or through elastomeric, ambulatory infusion, regional anesthesia, disposable infusion, or associated drug-delivery portfolios are Avanos Medical, Baxter International, B. Braun Medical, Nipro Corporation, Terumo Corporation, Fresenius Kabi, ICU Medical, Vygon, Leventon, Ambu, ACE Medical, Woo Young Medical, JMS, Daiken Medical, Epic Medical, Tuoren Medical, Teleflex, CODAN Companies, pfm medical, Progressive Medical, Ace Medical Products, KB Medical Group, and selected specialty infusion-device suppliers and private-label manufacturers serving U.S. pharmacy and hospital channels.

Avanos is particularly visible in postoperative analgesia through the ON-Q franchise and in elastomeric infusion through Homepump-related products. Its strength derives from clinician familiarity, regional anesthesia positioning, catheter integration, and a large installed protocol base.

Baxter remains important because of its broad hospital relationships and established disposable infusion portfolio. B. Braun benefits from integrated infusion, pharmacy, vascular-access, and medication-delivery capabilities, giving it relevance in health systems seeking supplier consolidation.

Nipro, Terumo, Fresenius Kabi, Vygon, Leventon, and other international manufacturers compete through product breadth, distribution relationships, pharmacy compatibility, and cost positioning. Epic Medical has also increased U.S. relevance through regulatory clearance activity for SMARTeZ elastomeric infusion technology.

Competitive advantage will increasingly depend on more than nominal pump performance. U.S. buyers evaluate complaint history, delivery consistency, filter and tubing design, fill process, drug compatibility, packaging, supply resilience, clinician training, contracting, customer service, and evidence supporting specific infusion protocols.

Hospital consolidation creates both an opportunity and a barrier. Winning an enterprise contract can generate recurring volume across multiple facilities, but health systems increasingly reduce the number of approved suppliers. Manufacturers without sufficient scale, inventory reliability, or contracting capability may find market access difficult even when their device performs well clinically.

 

Recent Developments

The U.S. elastomeric infusion-pump market has entered a more favorable reimbursement environment for selected postoperative pain applications. Beginning in 2025, qualifying non-opioid pain-management technologies became eligible for temporary separate Medicare payment under applicable hospital outpatient and ASC pathways. The ON-Q elastomeric pump category is specifically relevant to this policy environment, strengthening the financial case for certain non-opioid postoperative analgesia strategies.

Regulatory expectations are also changing. Elastomeric infusion pumps are Class II medical devices in the United States and generally fall under the FDA’s 510(k) framework. In February 2026, FDA’s Quality Management System Regulation became effective, aligning U.S. medical-device quality-system requirements more closely with ISO 13485:2016. For disposable infusion manufacturers, this increases the importance of rigorous supplier controls, complaint handling, risk management, process validation, and post-market quality systems.

Recent FDA activity also illustrates continued product innovation and competitive entry. New elastomeric pump configurations have received U.S. clearance, demonstrating that the category remains active despite the maturity of the fundamental technology.

At the same time, post-market performance remains an important commercial issue. Reported elastomeric pump malfunctions can include incomplete delivery, failure to deflate as expected, leakage, or inappropriate flow. Even when individual reports do not establish systemic product defects, they reinforce why hospitals and pharmacies increasingly evaluate supplier quality systems and field-performance history during procurement.

The next competitive cycle is therefore likely to revolve around reliability rather than radical hardware transformation. Products that provide reproducible flow, strong drug-compatibility documentation, intuitive visual confirmation of infusion progress, secure connections, reduced leakage risk, and simple pharmacy workflows will be better positioned than devices offering differentiation primarily through cosmetic design.

 

Conclusion

The U.S. Elastomeric Infusion Pumps Market Size & Share is expected to expand from approximately USD 0.23 billion in 2025 to approximately USD 0.50 billion by 2035, representing an 8.10% CAGR during 2026–2035. Historical market value is estimated to have increased from approximately USD 0.17 billion in 2021 to USD 0.21 billion in 2024 as oncology volumes normalized, outpatient procedures expanded, home infusion infrastructure matured, and hospitals increased focus on earlier discharge.

The long-term investment case is based less on technological disruption than on structural change in U.S. care delivery. Hospitals need to preserve acute-care capacity. Oncology centers need to improve infusion-chair productivity. Infection specialists need scalable pathways for appropriate outpatient antimicrobial therapy. ASCs need postoperative analgesia approaches compatible with same-day discharge. Patients increasingly expect treatment models that minimize unnecessary facility time. Elastomeric infusion pumps sit directly at the intersection of these priorities.

Antibiotic and OPAT applications should remain one of the largest recurring demand pools, while chemotherapy provides a resilient base of treatment-cycle consumption. Postoperative pain management represents a particularly important value-growth opportunity because outpatient surgery continues to expand and reimbursement policy has improved the economic visibility of qualifying non-opioid technologies.

Home infusion is expected to be the fastest-growing end-user category. Hospitals will remain the largest institutional decision makers, but a greater proportion of device utilization will ultimately occur beyond the hospital campus. Manufacturers therefore need commercial models that address health systems, specialty pharmacies, home infusion providers, oncology networks, and ambulatory surgery operators simultaneously.

Regional opportunity will remain strongest in the South because of population scale and rapid healthcare expansion. Texas and Florida will be critical volume markets, while North Carolina, Georgia, Tennessee, and Virginia offer strong growth. The West should generate the fastest percentage expansion, led by California and supported by Arizona, Nevada, Washington, Colorado, Oregon, and Utah. The Northeast will remain one of the most evidence-driven and clinically sophisticated markets, while the Midwest will provide a stable base of hospital, oncology, orthopedic, and OPAT demand.

For manufacturers, investors, distributors, specialty pharmacies, and health-system procurement teams evaluating the U.S. elastomeric infusion pump industry, the central commercial question is not whether disposable ambulatory infusion will remain relevant. It is which clinical pathways will shift most rapidly away from facility-based administration and which suppliers can make that transition operationally safe, financially attractive, and easy for clinicians and patients.

The winners through 2035 will be companies that combine dependable flow performance, strong pharmacy compatibility, broad reservoir and rate configurations, disciplined manufacturing quality, supply-chain reliability, favorable procedure economics, effective clinical education, and evidence that their devices support lower-complexity treatment outside conventional inpatient care. In that environment, elastomeric infusion pumps will increasingly be valued not as simple disposable balloons, but as enabling technologies for decentralized U.S. infusion care.

 

TABLE OF CONTENTS

1. U.S. Elastomeric Infusion Pumps Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Elastomeric Infusion Pump Manufacturers
1.6.2. Elastomer, Tubing, Flow Restrictor and Component Suppliers
1.6.3. Contract Manufacturing and Sterile Packaging Providers
1.6.4. Hospitals and Integrated Delivery Networks
1.6.5. Home Infusion Providers and Specialty Pharmacies
1.6.6. Oncology Centers and Ambulatory Infusion Facilities
1.6.7. Ambulatory Surgery Centers and Anesthesia Providers
1.6.8. Group Purchasing Organizations and Medical Distributors
1.6.9. Payers, Regulators and Clinical Decision-Makers

What this section provides: This section establishes the U.S. elastomeric infusion pumps market boundary, study scope, methodology, assumptions and stakeholder ecosystem, helping clients understand how market values, utilization patterns and forecasts are defined and validated.

2. U.S. Elastomeric Infusion Pumps Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. U.S. Market Size, 2021–2035 (US$ Billion)
2.8. CAGR Analysis, 2026–2035
2.9. High-Growth Opportunity Areas
2.10. Key Clinical Demand Pockets
2.11. Key Commercial and Procurement Takeaways

What this section provides: This section gives decision-makers a concise view of market size, historical development, 2025 positioning, forecast growth, major clinical demand pools, competitive intensity and priority investment opportunities through 2035.

3. U.S. Elastomeric Infusion Pumps Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Expansion of Home and Ambulatory Infusion Therapy
3.1.2. Growth of Outpatient Parenteral Antimicrobial Therapy (OPAT)
3.1.3. Rising Cancer Treatment and Ambulatory Chemotherapy Volumes
3.1.4. Shift Toward Outpatient Surgery and Same-Day Discharge
3.1.5. Expansion of Multimodal and Opioid-Sparing Postoperative Analgesia
3.1.6. Rising U.S. Geriatric Population and Chronic Disease Burden
3.1.7. Hospital Focus on Early Discharge and Bed-Capacity Optimization
3.1.8. Growth of Specialty Pharmacy and Home Infusion Infrastructure

3.2. Restraints and Their Impact Analysis
3.2.1. Flow-Rate Variability Under Real-World Conditions
3.2.2. Drug Stability and Compatibility Limitations
3.2.3. Temperature, Viscosity and Back-Pressure Sensitivity
3.2.4. Reimbursement Complexity for Disposable Infusion Technologies
3.2.5. Competition from Electronic Ambulatory and Syringe Pumps
3.2.6. Product Quality, Leakage and Incomplete Infusion Concerns

3.3. Opportunities and Their Impact Analysis
3.3.1. Hospital-at-Home and Decentralized Infusion Programs
3.3.2. Expansion of Continuous Antibiotic Infusion
3.3.3. Variable-Rate and Bolus-Capable Elastomeric Pumps
3.3.4. Ambulatory Oncology Workflow Optimization
3.3.5. Continuous Peripheral Nerve Block Applications
3.3.6. Specialty Pharmacy Partnerships and Integrated Infusion Pathways
3.3.7. Rural and Medically Underserved Home Infusion Opportunities
3.3.8. Digital Patient-Support Solutions Around Disposable Pumps

3.4. Challenges and Their Impact Analysis
3.4.1. Patient Education and Home-Use Compliance
3.4.2. Pharmacy Compounding and Filling Standardization
3.4.3. Device Disposal and Sustainability Considerations
3.4.4. Maintaining Supply Reliability for Single-Use Devices
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Clinical Workflow Economics Analysis
3.7. Hospital Discharge Economics Analysis
3.8. Home Infusion Episode-of-Care Economics
3.9. Hospital and Specialty Pharmacy Procurement Behavior Analysis

What this section provides: This section evaluates the clinical, economic, reimbursement, operational and competitive forces shaping elastomeric pump adoption and enables clients to identify market catalysts, adoption barriers and execution risks.

4. U.S. Elastomeric Infusion Pumps Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal

4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry

4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.4.1. Raw Material and Elastomer Supply
4.4.2. Flow Restrictor, Tubing and Connector Manufacturing
4.4.3. Pump Assembly and Sterilization
4.4.4. Packaging and Distribution
4.4.5. Hospital, Specialty Pharmacy and Home Infusion Distribution
4.5. Drug Compatibility and Stability Landscape
4.6. Pharmacy Compounding Workflow Analysis
4.7. Application & Innovation Landscape
4.8. Digitalization of Home Infusion and Patient Support
4.9. FDA Regulatory Framework Analysis
4.9.1. Class II Device Classification
4.9.2. 510(k) Premarket Notification Pathway
4.9.3. Quality Management System Requirements
4.9.4. Post-Market Surveillance and Medical Device Reporting
4.10. CMS Reimbursement and Coverage Landscape
4.10.1. Hospital Outpatient Reimbursement
4.10.2. Ambulatory Surgery Center Reimbursement
4.10.3. Home Infusion Reimbursement Considerations
4.10.4. Non-Opioid Pain Management Payment Environment
4.11. Import/Export Restrictions & Tariff Impact
4.12. Government Initiatives Supporting Home-Based Care
4.13. Impact of Escalating Geopolitical Tensions
4.14. Hospital Value Analysis Committee Decision Framework
4.15. Sustainability and Single-Use Medical Device Waste Analysis

What this section provides: This section delivers a comprehensive view of regulation, reimbursement, pricing, supply chain, pharmacy workflows, technology evolution, quality requirements, environmental pressures and institutional purchasing dynamics.

5. U.S. Elastomeric Infusion Pumps Market – By Product Type

5.1. Overview
5.1.1. Segment Share Analysis, By Product Type, 2025 & 2035 (%)
5.1.2. Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)

5.2. Continuous-Rate Elastomeric Infusion Pumps
5.2.1. Fixed-Flow Single-Rate Pumps
5.2.2. Continuous Multihour Infusion Pumps
5.2.3. Continuous Multiday Infusion Pumps

5.3. Variable-Rate Elastomeric Infusion Pumps
5.3.1. Adjustable Flow-Rate Pumps
5.3.2. Basal Rate Adjustable Pumps
5.3.3. Bolus-Capable Elastomeric Pumps
5.3.4. Patient-Controlled Analgesia Elastomeric Pumps

What this section provides: This section determines which elastomeric pump configurations are expected to generate the highest revenue contribution and identifies where adjustable-flow and bolus-capable technologies may gain share through 2035.

6. U.S. Elastomeric Infusion Pumps Market – By Application

6.1. Overview
6.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)
6.1.2. Market Size and Forecast, By Application, 2021–2035 (US$ Billion)

6.2. Antibiotics and OPAT
6.2.1. Continuous Antibiotic Infusion
6.2.2. Extended-Duration Antibiotic Infusion
6.2.3. Home-Based OPAT
6.2.4. Post-Discharge Infectious Disease Management

6.3. Chemotherapy
6.3.1. Fluorouracil-Based Continuous Chemotherapy
6.3.2. Gastrointestinal Cancer Therapy
6.3.3. Ambulatory Oncology Infusion
6.3.4. Other Continuous Antineoplastic Infusion

6.4. Pain Management and Postoperative Analgesia
6.4.1. Continuous Peripheral Nerve Block
6.4.2. Regional Anesthesia
6.4.3. Surgical-Site Local Anesthetic Infusion
6.4.4. Multimodal and Opioid-Sparing Pain Management

6.5. Chelation Therapy
6.5.1. Long-Duration Chelating Agent Infusion
6.5.2. Home-Based Chelation Therapy

6.6. Other Applications
6.6.1. Antiviral Therapy
6.6.2. Hydration and Supportive Care
6.6.3. Palliative Care Infusion
6.6.4. Other Specialty Medication Infusion

What this section provides: This section helps clients identify the clinical applications creating recurring pump utilization and highlights OPAT, oncology and postoperative analgesia as major strategic demand pools.

7. U.S. Elastomeric Infusion Pumps Market – By End User

7.1. Overview
7.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
7.1.2. Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

7.2. Hospitals and Health Systems
7.2.1. Academic Medical Centers
7.2.2. Community Hospitals
7.2.3. Integrated Delivery Networks
7.2.4. Hospital Outpatient Departments

7.3. Home Infusion and Home Healthcare Providers
7.3.1. Independent Home Infusion Providers
7.3.2. Health-System-Owned Home Infusion Services
7.3.3. Specialty Pharmacy-Based Infusion Providers
7.3.4. Home Healthcare Agencies

7.4. Ambulatory Surgery Centers
7.4.1. Orthopedic ASCs
7.4.2. Multispecialty ASCs
7.4.3. Hospital-Affiliated ASCs
7.4.4. Independent ASCs

7.5. Oncology and Specialty Infusion Centers
7.5.1. Hospital-Owned Cancer Centers
7.5.2. Community Oncology Practices
7.5.3. Independent Infusion Centers
7.5.4. Specialty Pharmacy-Integrated Infusion Centers

7.6. Skilled Nursing, Post-Acute and Other Providers
7.6.1. Skilled Nursing Facilities
7.6.2. Rehabilitation and Post-Acute Facilities
7.6.3. Physician Offices and Specialty Clinics
7.6.4. Palliative and Supportive Care Providers

What this section provides: This section explains which U.S. care settings generate elastomeric pump purchasing and utilization, with particular emphasis on the shift from hospital administration toward home infusion, ambulatory surgery and specialty infusion environments.

8. U.S. Elastomeric Infusion Pumps Market – By Reservoir Capacity

8.1. Overview
8.1.1. Segment Share Analysis, By Reservoir Capacity, 2025 & 2035 (%)
8.1.2. Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)

8.2. Less Than 100 mL
8.2.1. Low-Volume Postoperative Analgesia Pumps
8.2.2. Concentrated Medication Infusion Pumps

8.3. 100 mL to 250 mL
8.3.1. Standard Ambulatory Infusion Pumps
8.3.2. Antibiotic Infusion Pumps
8.3.3. Chemotherapy Infusion Pumps

8.4. More Than 250 mL
8.4.1. High-Capacity Continuous Infusion Pumps
8.4.2. Multiday Antibiotic Infusion Pumps
8.4.3. High-Volume Postoperative Analgesia Pumps

What this section provides: This section evaluates demand by reservoir capacity and helps clients understand how therapy duration, medication concentration, portability and pharmacy filling requirements influence pump-selection behavior.

9. U.S. Elastomeric Infusion Pumps Market: Procurement, Pricing & Channel Intelligence

9.1. U.S. Procurement Landscape Overview
9.2. Direct Hospital and Health System Procurement
9.3. Integrated Delivery Network Enterprise Contracts
9.4. Group Purchasing Organization Influence
9.5. Specialty Pharmacy Procurement
9.6. Home Infusion Provider Procurement
9.7. Oncology Network Procurement
9.8. Ambulatory Surgery Center Procurement
9.9. Distributor and Medical-Surgical Channel Sales
9.10. Private-Label and OEM Supply Models
9.11. Value Analysis Committee Evaluation Criteria
9.12. Contract Pricing and Volume Discount Structures
9.13. Device Standardization Across Health Systems
9.14. Supply Continuity and Dual-Sourcing Strategies
9.15. Total Cost Per Infusion Episode Analysis
9.16. Procurement Decision Matrix, 2025–2035

What this section provides: This section explains how elastomeric infusion pumps are sourced, evaluated and contracted in the United States, including IDN standardization, GPO influence, specialty pharmacy purchasing, distributor relationships and total episode-of-care economics.

10. U.S. Elastomeric Infusion Pumps Market – By Geography
10.1. Introduction

10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Infusion Volume and Healthcare Infrastructure Analysis
10.1.4. Regional Home Infusion and Specialty Pharmacy Penetration
10.1.5. Regional Oncology and OPAT Demand Analysis
10.1.6. Regional Ambulatory Surgery and Postoperative Analgesia Analysis
10.1.7. Regional Reimbursement and Procurement Dynamics

10.2. West Region

10.2.1. Regional Overview & Trends
10.2.2. West Region Key Manufacturers, Distributors, Home Infusion Providers and Procurement Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.2.8. West Region Procurement, Specialty Pharmacy and Home Infusion Channel Analysis

10.2.9. California

10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.2.9.6. California Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.2.10. Washington

10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.2.10.6. Washington Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.2.11. Arizona

10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.2.11.6. Arizona Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.2.12. Colorado

10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.2.12.6. Colorado Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.2.13. Oregon

10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.2.13.6. Oregon Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.2.14. Utah

10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.2.14.6. Utah Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.2.15. Nevada

10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.2.15.6. Nevada Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.2.16. New Mexico

10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.2.16.6. New Mexico Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.2.17. Idaho

10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.2.17.6. Idaho Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.2.18. Montana

10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.2.18.6. Montana Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.2.19. Wyoming

10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.2.19.6. Wyoming Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.2.20. Alaska

10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.2.20.6. Alaska Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.2.21. Hawaii

10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.2.21.6. Hawaii Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.3. Northeast Region

10.3.1. Regional Overview & Trends
10.3.2. Northeast Region Key Manufacturers, Distributors, Home Infusion Providers and Procurement Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.3.8. Northeast Region Procurement, Specialty Pharmacy and Home Infusion Channel Analysis

10.3.9. New York

10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.3.9.6. New York Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.3.10. Massachusetts

10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.3.10.6. Massachusetts Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.3.11. New Jersey

10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.3.11.6. New Jersey Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.3.12. Pennsylvania

10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.3.12.6. Pennsylvania Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.3.13. Connecticut

10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.3.13.6. Connecticut Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.3.14. Maine

10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.3.14.6. Maine Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.3.15. Vermont

10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.3.15.6. Vermont Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.3.16. New Hampshire

10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.3.16.6. New Hampshire Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.3.17. Rhode Island

10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.3.17.6. Rhode Island Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.3.18. Delaware

10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.18.3. Delaware Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.18.4. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.18.5. Delaware Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.3.18.6. Delaware Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.4. South Region

10.4.1. Regional Overview & Trends
10.4.2. South Region Key Manufacturers, Distributors, Home Infusion Providers and Procurement Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.4.8. South Region Procurement, Specialty Pharmacy and Home Infusion Channel Analysis

10.4.9. Texas

10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.4.9.6. Texas Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.4.10. Florida

10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.4.10.6. Florida Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.4.11. Georgia

10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.4.11.6. Georgia Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.4.12. North Carolina

10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.4.12.6. North Carolina Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.4.13. Tennessee

10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.4.13.6. Tennessee Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.4.14. South Carolina

10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.4.14.6. South Carolina Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.4.15. Alabama

10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.4.15.6. Alabama Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.4.16. Mississippi

10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.4.16.6. Mississippi Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.4.17. Louisiana

10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.4.17.6. Louisiana Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.4.18. Arkansas

10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.4.18.6. Arkansas Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.4.19. Kentucky

10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.4.19.6. Kentucky Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.4.20. Oklahoma

10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.4.20.6. Oklahoma Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.4.21. Virginia

10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.4.21.6. Virginia Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.4.22. Maryland

10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.4.22.6. Maryland Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.4.23. West Virginia

10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.4.23.6. West Virginia Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.5. Midwest Region

10.5.1. Regional Overview & Trends
10.5.2. Midwest Region Key Manufacturers, Distributors, Home Infusion Providers and Procurement Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.5.8. Midwest Region Procurement, Specialty Pharmacy and Home Infusion Channel Analysis

10.5.9. Illinois

10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.5.9.6. Illinois Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.5.10. Ohio

10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.5.10.6. Ohio Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.5.11. Michigan

10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.5.11.6. Michigan Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.5.12. Minnesota

10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.5.12.6. Minnesota Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.5.13. Indiana

10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.5.13.6. Indiana Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.5.14. Wisconsin

10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.5.14.6. Wisconsin Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.5.15. Missouri

10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.5.15.6. Missouri Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.5.16. Iowa

10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.5.16.6. Iowa Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.5.17. Kansas

10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.5.17.6. Kansas Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.5.18. Nebraska

10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.5.18.6. Nebraska Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.5.19. North Dakota

10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.5.19.6. North Dakota Procurement, Home Infusion and Specialty Pharmacy Ecosystem

10.5.20. South Dakota

10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By Reservoir Capacity, 2021–2035 (US$ Billion)
10.5.20.6. South Dakota Procurement, Home Infusion and Specialty Pharmacy Ecosystem

What this section provides: This section delivers detailed regional and state-level analysis across all 50 states, helping clients identify priority U.S. geographies, home-infusion hubs, oncology demand centers, OPAT opportunities, outpatient surgery markets, procurement patterns and state-level commercial opportunities.

11. U.S. Elastomeric Infusion Pumps Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Competitive Benchmarking Analysis
11.3. Company Positioning Matrix
11.3.1. Leaders
11.3.2. Challengers
11.3.3. Innovators
11.3.4. Emerging Players
11.4. Competitive Intensity by Application
11.5. Portfolio Breadth and Product Configuration Benchmarking
11.6. Flow-Rate and Reservoir Portfolio Comparison
11.7. U.S. Distribution and Channel Positioning
11.8. Regulatory and Product Clearance Benchmarking
11.9. Company Profiles

11.9.1. Avanos Medical, Inc.
11.9.2. Baxter International Inc.
11.9.3. B. Braun Medical Inc.
11.9.4. Nipro Corporation
11.9.5. Terumo Corporation
11.9.6. Fresenius Kabi
11.9.7. ICU Medical, Inc.
11.9.8. Vygon
11.9.9. Leventon S.A.U.
11.9.10. Epic Medical
11.9.11. ACE Medical Co., Ltd.
11.9.12. Woo Young Medical Co., Ltd.
11.9.13. JMS Co., Ltd.
11.9.14. Daiken Medical Co., Ltd.
11.9.15. Tuoren Medical
11.9.16. Teleflex Incorporated
11.9.17. CODAN Companies
11.9.18. pfm medical
11.9.19. Progressive Medical, Inc.
11.9.20. KB Medical Group
11.9.21. Micrel Medical Devices
11.9.22. Cardinal Health
11.9.23. McKesson Medical-Surgical
11.9.24. Medline Industries

Note: Each company profile will include company overview, elastomeric infusion pump or relevant ambulatory infusion portfolio, U.S. market presence, product positioning, regulatory status, channel strategy, clinical focus, strategic partnerships and recent developments. Distributor profiles will specifically evaluate their role in U.S. elastomeric infusion pump market access and procurement.

What this section provides: This section provides competitor benchmarking, market-share visibility, product portfolio positioning, U.S. channel intelligence, regulatory positioning and strategic analysis of leading elastomeric infusion pump manufacturers and market-access participants.

12. U.S. Elastomeric Infusion Pumps Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario

12.2. Technology and Workflow Innovations Impacting Market Growth
12.2.1. Advanced Flow-Control Technologies
12.2.2. Variable-Rate and Bolus-Capable Systems
12.2.3. Next-Generation Elastomer and Reservoir Materials
12.2.4. Digital Patient Instruction and Remote Support
12.2.5. Pharmacy Compounding Automation
12.2.6. Drug Stability and Compatibility Innovation
12.2.7. Lower-Waste and Sustainable Disposable Pump Design

12.3. Emerging Clinical Care Trends
12.3.1. Hospital-at-Home Expansion
12.3.2. Decentralized Oncology Care
12.3.3. Growth of Continuous OPAT
12.3.4. Outpatient Orthopedic Surgery Expansion
12.3.5. Opioid-Sparing Postoperative Care

12.4. Emerging Business Trends
12.5. Business Opportunities for Startups and Existing Players
12.6. White-Space Opportunity Analysis
12.7. Investment Prioritization Matrix
12.8. High-Growth State Opportunity Matrix
12.9. Market Outlook Beyond 2035

What this section provides: This section prepares clients for future changes in infusion delivery, home-based treatment, pharmacy operations, reimbursement, technology development and competitive structure while identifying the most attractive investment and expansion opportunities through 2035.

13. U.S. Elastomeric Infusion Pumps Market: Strategic Recommendations

13.1. Recommendations for Elastomeric Infusion Pump Manufacturers
13.2. Recommendations for Hospitals and Integrated Delivery Networks
13.3. Recommendations for Home Infusion Providers
13.4. Recommendations for Specialty Pharmacies
13.5. Recommendations for Oncology Networks
13.6. Recommendations for Ambulatory Surgery Centers
13.7. Recommendations for Investors and Private Equity Firms
13.8. Recommendations for Distributors and Channel Partners
13.9. Recommendations for New Entrants and Startups
13.10. Go-to-Market Strategy Considerations
13.11. Product Positioning and Portfolio Expansion Guidance
13.12. Hospital Value Analysis Committee Engagement Strategy
13.13. GPO and IDN Contracting Strategy
13.14. U.S. State-Level Commercial Prioritization
13.15. M&A and Strategic Partnership Opportunities

What this section provides: This section converts market intelligence into actionable strategies for product development, market entry, portfolio expansion, hospital contracting, specialty pharmacy partnerships, geographic prioritization, investment decisions and competitive differentiation.

14. U.S. Elastomeric Infusion Pumps Market: Disclaimer

14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Forecasting Limitation
14.4. Market Estimation Limitation
14.5. Legal Disclaimer
14.6. Third-Party Data Disclaimer
14.7. Regulatory and Reimbursement Disclaimer

What this section provides: This section clarifies the report’s scope limitations, forecasting assumptions, data-use boundaries, regulatory considerations and legal conditions governing interpretation of the U.S. Elastomeric Infusion Pumps Market report.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Elastomeric Infusion Pumps Market: Market Definition and Scope
TABLE 3: U.S. Elastomeric Infusion Pumps Market: Research Methodology Framework
TABLE 4: U.S. Elastomeric Infusion Pumps Market: Key Assumptions
TABLE 5: U.S. Elastomeric Infusion Pumps Market: Market Ecosystem Overview
TABLE 6: U.S. Elastomeric Infusion Pumps Market: Stakeholder Analysis
TABLE 7: U.S. Elastomeric Infusion Pumps Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Elastomeric Infusion Pumps Market: Analyst Viewpoint Summary
TABLE 9: U.S. Elastomeric Infusion Pumps Market: Market Attractiveness Index
TABLE 10: U.S. Elastomeric Infusion Pumps Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Elastomeric Infusion Pumps Market: Base Year Market Positioning, 2025
TABLE 12: U.S. Elastomeric Infusion Pumps Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 13: U.S. Elastomeric Infusion Pumps Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 14: U.S. Elastomeric Infusion Pumps Market: Drivers; Impact Analysis
TABLE 15: U.S. Elastomeric Infusion Pumps Market: Restraints; Impact Analysis
TABLE 16: U.S. Elastomeric Infusion Pumps Market: Opportunities; Impact Analysis
TABLE 17: U.S. Elastomeric Infusion Pumps Market: Challenges; Impact Analysis
TABLE 18: U.S. Elastomeric Infusion Pumps Market: Patent & Innovation Analysis, 2021–2025
TABLE 19: U.S. Elastomeric Infusion Pumps Market: Clinical Workflow Economics Matrix
TABLE 20: U.S. Elastomeric Infusion Pumps Market: Hospital Discharge Economics Analysis
TABLE 21: U.S. Elastomeric Infusion Pumps Market: Home Infusion Episode-of-Care Economics
TABLE 22: U.S. Elastomeric Infusion Pumps Market: PESTEL Analysis
TABLE 23: U.S. Elastomeric Infusion Pumps Market: Porter’s Five Forces Analysis
TABLE 24: U.S. Elastomeric Infusion Pumps Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 25: U.S. Elastomeric Infusion Pumps Market: Value Chain Analysis
TABLE 26: U.S. Elastomeric Infusion Pumps Market: Supply Chain Analysis
TABLE 27: U.S. Elastomeric Infusion Pumps Market: Drug Compatibility and Stability Landscape
TABLE 28: U.S. Elastomeric Infusion Pumps Market: Pharmacy Compounding Workflow Analysis
TABLE 29: U.S. Elastomeric Infusion Pumps Market: Application & Innovation Landscape
TABLE 30: U.S. Elastomeric Infusion Pumps Market: Digitalization of Home Infusion and Patient Support
TABLE 31: U.S. Elastomeric Infusion Pumps Market: FDA Regulatory Framework Analysis
TABLE 32: U.S. Elastomeric Infusion Pumps Market: CMS Reimbursement and Coverage Landscape
TABLE 33: U.S. Elastomeric Infusion Pumps Market: Import/Export Restrictions & Tariff Impact
TABLE 34: U.S. Elastomeric Infusion Pumps Market: Government Initiatives Supporting Home-Based Care
TABLE 35: U.S. Elastomeric Infusion Pumps Market: Impact of Escalating Geopolitical Tensions
TABLE 36: U.S. Elastomeric Infusion Pumps Market: Hospital Value Analysis Committee Decision Framework
TABLE 37: U.S. Elastomeric Infusion Pumps Market: Product Type Snapshot, 2025
TABLE 38: Segment Dashboard; Definition and Scope, by Product Type
TABLE 39: U.S. Elastomeric Infusion Pumps Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 40: U.S. Elastomeric Infusion Pumps Market: Segment Share Analysis, by Product Type, 2025 & 2035 (%)
TABLE 41: U.S. Elastomeric Infusion Pumps Market: Continuous-Rate Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 42: U.S. Elastomeric Infusion Pumps Market: Variable-Rate Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 43: U.S. Elastomeric Infusion Pumps Market: Application Snapshot, 2025
TABLE 44: Segment Dashboard; Definition and Scope, by Application
TABLE 45: U.S. Elastomeric Infusion Pumps Market, by Application, 2021–2035 (US$ Billion)
TABLE 46: U.S. Elastomeric Infusion Pumps Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 47: U.S. Elastomeric Infusion Pumps Market: Antibiotics and OPAT Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 48: U.S. Elastomeric Infusion Pumps Market: Chemotherapy Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 49: U.S. Elastomeric Infusion Pumps Market: Pain Management and Postoperative Analgesia Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 50: U.S. Elastomeric Infusion Pumps Market: Chelation Therapy Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 51: U.S. Elastomeric Infusion Pumps Market: Other Applications Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 52: U.S. Elastomeric Infusion Pumps Market: End User Snapshot, 2025
TABLE 53: Segment Dashboard; Definition and Scope, by End User
TABLE 54: U.S. Elastomeric Infusion Pumps Market, by End User, 2021–2035 (US$ Billion)
TABLE 55: U.S. Elastomeric Infusion Pumps Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 56: U.S. Elastomeric Infusion Pumps Market: Hospitals and Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: U.S. Elastomeric Infusion Pumps Market: Home Infusion and Home Healthcare Providers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 58: U.S. Elastomeric Infusion Pumps Market: Ambulatory Surgery Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 59: U.S. Elastomeric Infusion Pumps Market: Oncology and Specialty Infusion Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 60: U.S. Elastomeric Infusion Pumps Market: Skilled Nursing, Post-Acute and Other Providers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 61: U.S. Elastomeric Infusion Pumps Market: Reservoir Capacity Snapshot, 2025
TABLE 62: Segment Dashboard; Definition and Scope, by Reservoir Capacity
TABLE 63: U.S. Elastomeric Infusion Pumps Market, by Reservoir Capacity, 2021–2035 (US$ Billion)
TABLE 64: U.S. Elastomeric Infusion Pumps Market: Segment Share Analysis, by Reservoir Capacity, 2025 & 2035 (%)
TABLE 65: U.S. Elastomeric Infusion Pumps Market: Less Than 100 mL Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 66: U.S. Elastomeric Infusion Pumps Market: 100 mL to 250 mL Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 67: U.S. Elastomeric Infusion Pumps Market: More Than 250 mL Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 68: U.S. Elastomeric Infusion Pumps Market: Procurement Landscape Snapshot, 2025
TABLE 69: U.S. Elastomeric Infusion Pumps Market: Direct Hospital and Health System Procurement Analysis
TABLE 70: U.S. Elastomeric Infusion Pumps Market: GPO and IDN Contracting Analysis
TABLE 71: U.S. Elastomeric Infusion Pumps Market: Specialty Pharmacy and Home Infusion Procurement Analysis
TABLE 72: U.S. Elastomeric Infusion Pumps Market: Oncology and ASC Procurement Analysis
TABLE 73: U.S. Elastomeric Infusion Pumps Market: Distributor and Medical-Surgical Channel Analysis
TABLE 74: U.S. Elastomeric Infusion Pumps Market: Contract Pricing and Volume Discount Analysis
TABLE 75: U.S. Elastomeric Infusion Pumps Market: Total Cost per Infusion Episode and Procurement Decision Matrix
TABLE 76: U.S. Elastomeric Infusion Pumps Market: Regional Snapshot, 2025
TABLE 77: Segment Dashboard; Definition and Scope, by Geography
TABLE 78: U.S. Elastomeric Infusion Pumps Market, by Region, 2021–2035 (US$ Billion)
TABLE 79: U.S. Elastomeric Infusion Pumps Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 80: West Region U.S. Elastomeric Infusion Pumps Market: Regional Overview and Trends
TABLE 81: West Region U.S. Elastomeric Infusion Pumps Market: Key Manufacturers and Procurement Ecosystem
TABLE 82: West Region U.S. Elastomeric Infusion Pumps Market, by State, 2021–2035 (US$ Billion)
TABLE 83: West Region U.S. Elastomeric Infusion Pumps Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 84: West Region U.S. Elastomeric Infusion Pumps Market, by Application, 2021–2035 (US$ Billion)
TABLE 85: West Region U.S. Elastomeric Infusion Pumps Market, by End User and Reservoir Capacity, 2021–2035 (US$ Billion)
TABLE 86: California Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 87: Washington Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 88: Arizona Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 89: Colorado Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 90: Oregon Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 91: Utah Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 92: Nevada Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 93: New Mexico Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 94: Idaho Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 95: Montana Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 96: Wyoming Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 97: Alaska Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 98: Hawaii Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 99: Northeast Region U.S. Elastomeric Infusion Pumps Market: Regional Overview and Trends
TABLE 100: Northeast Region U.S. Elastomeric Infusion Pumps Market: Key Manufacturers and Procurement Ecosystem
TABLE 101: Northeast Region U.S. Elastomeric Infusion Pumps Market, by State, 2021–2035 (US$ Billion)
TABLE 102: Northeast Region U.S. Elastomeric Infusion Pumps Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 103: Northeast Region U.S. Elastomeric Infusion Pumps Market, by Application, 2021–2035 (US$ Billion)
TABLE 104: Northeast Region U.S. Elastomeric Infusion Pumps Market, by End User and Reservoir Capacity, 2021–2035 (US$ Billion)
TABLE 105: New York Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 106: Massachusetts Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 107: New Jersey Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 108: Pennsylvania Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 109: Connecticut Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 110: Maine Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 111: Vermont Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 112: New Hampshire Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 113: Rhode Island Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 114: Delaware Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 115: South Region U.S. Elastomeric Infusion Pumps Market: Regional Overview and Trends
TABLE 116: South Region U.S. Elastomeric Infusion Pumps Market: Key Manufacturers and Procurement Ecosystem
TABLE 117: South Region U.S. Elastomeric Infusion Pumps Market, by State, 2021–2035 (US$ Billion)
TABLE 118: South Region U.S. Elastomeric Infusion Pumps Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 119: South Region U.S. Elastomeric Infusion Pumps Market, by Application, 2021–2035 (US$ Billion)
TABLE 120: South Region U.S. Elastomeric Infusion Pumps Market, by End User and Reservoir Capacity, 2021–2035 (US$ Billion)
TABLE 121: Texas Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 122: Florida Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 123: Georgia Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 124: North Carolina Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 125: Tennessee Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 126: South Carolina Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 127: Alabama Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 128: Mississippi Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 129: Louisiana Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 130: Arkansas Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 131: Kentucky Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 132: Oklahoma Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 133: Virginia Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 134: Maryland Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 135: West Virginia Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 136: Midwest Region U.S. Elastomeric Infusion Pumps Market: Regional Overview and Trends
TABLE 137: Midwest Region U.S. Elastomeric Infusion Pumps Market: Key Manufacturers and Procurement Ecosystem
TABLE 138: Midwest Region U.S. Elastomeric Infusion Pumps Market, by State, 2021–2035 (US$ Billion)
TABLE 139: Midwest Region U.S. Elastomeric Infusion Pumps Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 140: Midwest Region U.S. Elastomeric Infusion Pumps Market, by Application, 2021–2035 (US$ Billion)
TABLE 141: Midwest Region U.S. Elastomeric Infusion Pumps Market, by End User and Reservoir Capacity, 2021–2035 (US$ Billion)
TABLE 142: Illinois Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 143: Ohio Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 144: Michigan Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 145: Minnesota Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 146: Indiana Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 147: Wisconsin Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 148: Missouri Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 149: Iowa Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 150: Kansas Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 151: Nebraska Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 152: North Dakota Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 153: South Dakota Elastomeric Infusion Pumps Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 154: U.S. Elastomeric Infusion Pumps Market: Competitive Landscape Snapshot, 2025
TABLE 155: U.S. Elastomeric Infusion Pumps Market: Key Company Market Share Analysis, 2025
TABLE 156: U.S. Elastomeric Infusion Pumps Market: Company Positioning Matrix
TABLE 157: U.S. Elastomeric Infusion Pumps Market: Product Portfolio Benchmarking of Key Players
TABLE 158: U.S. Elastomeric Infusion Pumps Market: Flow-Rate and Reservoir Portfolio Comparison
TABLE 159: U.S. Elastomeric Infusion Pumps Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 160: Avanos Medical, Inc.: Company Profile
TABLE 161: Baxter International Inc.: Company Profile
TABLE 162: B. Braun Medical Inc.: Company Profile
TABLE 163: Nipro Corporation: Company Profile
TABLE 164: Terumo Corporation: Company Profile
TABLE 165: Fresenius Kabi: Company Profile
TABLE 166: ICU Medical, Inc.: Company Profile
TABLE 167: Vygon: Company Profile
TABLE 168: Leventon S.A.U.: Company Profile
TABLE 169: Epic Medical: Company Profile
TABLE 170: ACE Medical Co., Ltd.: Company Profile
TABLE 171: Woo Young Medical Co., Ltd.: Company Profile
TABLE 172: JMS Co., Ltd.: Company Profile
TABLE 173: Daiken Medical Co., Ltd.: Company Profile
TABLE 174: Tuoren Medical: Company Profile
TABLE 175: Teleflex Incorporated: Company Profile
TABLE 176: CODAN Companies: Company Profile
TABLE 177: pfm medical: Company Profile
TABLE 178: Progressive Medical, Inc.: Company Profile
TABLE 179: KB Medical Group: Company Profile
TABLE 180: Micrel Medical Devices: Company Profile
TABLE 181: Cardinal Health: Company Profile
TABLE 182: McKesson Medical-Surgical: Company Profile
TABLE 183: Medline Industries: Company Profile
TABLE 184: U.S. Elastomeric Infusion Pumps Market: Future Market Scenario Analysis, 2026–2035
TABLE 185: U.S. Elastomeric Infusion Pumps Market: Technology and Workflow Innovation Impact Matrix
TABLE 186: U.S. Elastomeric Infusion Pumps Market: Emerging Clinical Care Trends
TABLE 187: U.S. Elastomeric Infusion Pumps Market: Emerging Business Trends
TABLE 188: U.S. Elastomeric Infusion Pumps Market: White-Space Opportunities for Existing and Emerging Players
TABLE 189: U.S. Elastomeric Infusion Pumps Market: Investment and High-Growth State Prioritization Matrix
TABLE 190: U.S. Elastomeric Infusion Pumps Market: Strategic Recommendations for Manufacturers
TABLE 191: U.S. Elastomeric Infusion Pumps Market: Strategic Recommendations for Hospitals and IDNs
TABLE 192: U.S. Elastomeric Infusion Pumps Market: Strategic Recommendations for Home Infusion Providers and Specialty Pharmacies
TABLE 193: U.S. Elastomeric Infusion Pumps Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 194: U.S. Elastomeric Infusion Pumps Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 195: U.S. Elastomeric Infusion Pumps Market: Strategic Recommendations for New Entrants and Startups
TABLE 196: U.S. Elastomeric Infusion Pumps Market: Go-to-Market and State-Level Commercial Prioritization
TABLE 197: U.S. Elastomeric Infusion Pumps Market: Product Positioning and Portfolio Expansion Guidance
TABLE 198: U.S. Elastomeric Infusion Pumps Market: Scope Limitation
TABLE 199: U.S. Elastomeric Infusion Pumps Market: Data Use Limitation
TABLE 200: U.S. Elastomeric Infusion Pumps Market: Forecasting and Market Estimation Limitation
TABLE 201: U.S. Elastomeric Infusion Pumps Market: Legal Disclaimer
TABLE 202: U.S. Elastomeric Infusion Pumps Market: Third-Party Data, Regulatory and Reimbursement Disclaimer

List of Figures

FIGURE 1: U.S. Elastomeric Infusion Pumps Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: U.S. Elastomeric Infusion Pumps Market Ecosystem
FIGURE 4: Stakeholder Landscape
FIGURE 5: U.S. Elastomeric Infusion Pumps Market Attractiveness Analysis
FIGURE 6: U.S. Elastomeric Infusion Pumps Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 7: U.S. Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 8: U.S. Elastomeric Infusion Pumps Market Year-wise Growth Curve, 2021–2035
FIGURE 9: U.S. Elastomeric Infusion Pumps Market Dynamics
FIGURE 10: Innovation & Patent Landscape, 2021–2025
FIGURE 11: Clinical Workflow Economics Framework
FIGURE 12: Hospital Discharge and Home Infusion Economics Framework
FIGURE 13: Elastomeric Pump Procurement Decision Framework
FIGURE 14: PESTEL Analysis
FIGURE 15: Porter’s Five Forces Analysis
FIGURE 16: Value Chain Analysis
FIGURE 17: Supply Chain Analysis
FIGURE 18: Drug Compatibility and Pharmacy Compounding Workflow
FIGURE 19: FDA Regulatory and CMS Reimbursement Landscape
FIGURE 20: Hospital Value Analysis Committee Decision Framework
FIGURE 21: Product Type Segment Market Share Analysis, 2025 & 2035
FIGURE 22: Product Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 23: Continuous-Rate Elastomeric Infusion Pumps Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 24: Variable-Rate Elastomeric Infusion Pumps Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 25: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 26: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Antibiotics and OPAT Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Chemotherapy Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Pain Management and Postoperative Analgesia Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: Chelation Therapy Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: Other Applications Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 32: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 33: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: Hospitals and Health Systems Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 35: Home Infusion and Home Healthcare Providers Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 36: Ambulatory Surgery Centers Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 37: Oncology and Specialty Infusion Centers Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 38: Skilled Nursing, Post-Acute and Other Providers Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 39: Reservoir Capacity Segment Market Share Analysis, 2025 & 2035
FIGURE 40: Reservoir Capacity Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Less Than 100 mL Pumps Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 42: 100 mL to 250 mL Pumps Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 43: More Than 250 mL Pumps Market Size Forecast, 2021–2035 (US$ Billion)
FIGURE 44: U.S. Elastomeric Infusion Pumps Procurement Ecosystem
FIGURE 45: GPO, IDN and Specialty Pharmacy Contracting Framework
FIGURE 46: Elastomeric Infusion Pump Total Cost per Episode Framework
FIGURE 47: Procurement Channel and Decision-Making Matrix
FIGURE 48: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 49: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: West Region U.S. Elastomeric Infusion Pumps Market Share and Demand Landscape, 2025
FIGURE 51: West Region Market Share Analysis by State, 2025
FIGURE 52: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 53: California Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 54: Washington Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 55: Arizona Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 56: Colorado Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 57: Oregon Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 58: Utah Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 59: Nevada Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 60: New Mexico Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 61: Idaho Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 62: Montana Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 63: Wyoming Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 64: Alaska Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 65: Hawaii Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 66: Northeast Region U.S. Elastomeric Infusion Pumps Market Share and Demand Landscape, 2025
FIGURE 67: Northeast Region Market Share Analysis by State, 2025
FIGURE 68: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: New York Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 70: Massachusetts Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 71: New Jersey Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 72: Pennsylvania Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 73: Connecticut Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 74: Maine Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 75: Vermont Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 76: New Hampshire Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 77: Rhode Island Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 78: Delaware Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 79: South Region U.S. Elastomeric Infusion Pumps Market Share and Demand Landscape, 2025
FIGURE 80: South Region Market Share Analysis by State, 2025
FIGURE 81: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: Texas Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 83: Florida Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 84: Georgia Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 85: North Carolina Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 86: Tennessee Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 87: South Carolina Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 88: Alabama Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 89: Mississippi Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 90: Louisiana Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 91: Arkansas Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 92: Kentucky Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 93: Oklahoma Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 94: Virginia Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 95: Maryland Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 96: West Virginia Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 97: Midwest Region U.S. Elastomeric Infusion Pumps Market Share and Demand Landscape, 2025
FIGURE 98: Midwest Region Market Share Analysis by State, 2025
FIGURE 99: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: Illinois Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 101: Ohio Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 102: Michigan Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 103: Minnesota Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 104: Indiana Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 105: Wisconsin Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 106: Missouri Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 107: Iowa Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 108: Kansas Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 109: Nebraska Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 110: North Dakota Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 111: South Dakota Elastomeric Infusion Pumps Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 112: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 113: Company Positioning Matrix
FIGURE 114: Key Player Product Portfolio Benchmarking
FIGURE 115: Flow-Rate and Reservoir Portfolio Benchmarking
FIGURE 116: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 117: U.S. Elastomeric Infusion Pumps Innovation Roadmap
FIGURE 118: Home Infusion and OPAT Adoption Roadmap
FIGURE 119: Ambulatory Oncology Infusion Opportunity Map
FIGURE 120: Postoperative Analgesia and ASC Growth Roadmap
FIGURE 121: Future Market Scenario Analysis, 2026–2035
FIGURE 122: Technology and Workflow Innovation Impact Matrix
FIGURE 123: Emerging Clinical and Business Trends Matrix
FIGURE 124: White-Space Opportunity Matrix
FIGURE 125: Investment and High-Growth State Prioritization Matrix
FIGURE 126: Strategic Growth Roadmap for U.S. Elastomeric Infusion Pump Companies
FIGURE 127: Go-to-Market Strategy Framework
FIGURE 128: Product Positioning and Portfolio Expansion Framework
FIGURE 129: Report Scope, Forecasting and Disclaimer Framework